Menu
Search
|

Menu

Close
X

Proteostasis Therapeutics Inc PTI.OQ (NASDAQ Stock Exchange Global Market)

2.85 USD
-- (--)
As of Jul 13
chart
Previous Close 2.85
Open --
Volume --
3m Avg Volume 344,797
Today’s High --
Today’s Low --
52 Week High 8.61
52 Week Low 1.41
Shares Outstanding (mil) 36.08
Market Capitalization (mil) 102.83
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
5
FY16
8
FY15
4
EPS (USD)
FY18
-0.320
FY17
-2.344
FY16
-2.256
FY15
-1.220
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
19.54
8.07
Price to Book (MRQ)
vs sector
1.63
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
0.00
17.39
LT Debt to Equity (MRQ)
vs sector
0.00
13.21
Return on Investment (TTM)
vs sector
-78.23
13.23
Return on Equity (TTM)
vs sector
-87.03
15.28

EXECUTIVE LEADERSHIP

M. James Barrett
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Meenu Chhabra
President, Chief Executive Officer, Director, Since 2014
Salary: $450,138.00
Bonus: $232,500.00
Marija Zecevic
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Po-Shun Lee
Executive Vice President, Chief Medical Officer, Since
Salary: $334,892.00
Bonus: $119,000.00
Benito Munoz
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

80 Guest St Fl 5
BOSTON   MA   02135-2028

Phone: +1617.2250096

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

SPONSORED STORIES